enVVeno Medical Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
48.1%projected annual EPS growth
Analyst Coverage
1analyst covering
FY EPS (est.)
-$16.19next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Investments Balance Quarterly24.9MTarget: Sufficient to fund operations into Q3 2027
Quarterly Cash Burn Rate Quarterly3.3MTarget: 3000000 to 4000000
TAVVE Pivotal Study Enrollment Quarterly0.0
Watch Items
- TAVVE Study Stage 1 Safety Cohort SubmissionTrigger: Completion of 30-day safety follow-up for the first 10 patientsAction: Submit 30-day safety data to the FDA to obtain clearance to proceed to Stage 2 (enrolling remaining 220 patients)
- Quarterly Cash Burn AccelerationTrigger: Exceeding $5.0 million per quarterAction: Evaluate utilization of the remaining At-The-Market (ATM) equity program capacity of $48.8 million to extend runway
Research as of 20 Jun 2026